10 cfu/mL and Str. agalactiae SAG 3 in a concentration of 4 x 10 9 cfu/mL. The number of somatic cells in the milk samples during the whole study period was higher in vaccinated cows in both groups compared with the control, higher than the concentration of this class of proteins in the milk of unvaccinated cows.
INTRODUCTION
Immunoprophylaxis against mastitis pathogens during the '70ties was based on polyvaccines, which consisted of immunogenic strains of staphylococci, streptococci and coliform bacteria, exotoxins and endotoxins. Polyvalent vaccines have not proven to be successful, and their production was abandoned in favor of monovalent vaccines, which gave much better results. The vaccine against Staphylococcus aureus contains inactive S. aureus cells (Giraudo, 1997; Hoedermaker, 1999) , as well as Str. agalactiae cells (Giraudo, 1997) . A large number of studies indicate that in order to obtain an improved inactivated vaccine alpha and beta toxoids are added to S. aureus, as well as fragments of its capsule (Calzolari, 1997; Watson, 1996) . Keskin et al. (2007) described the effects of a commercial vaccine which contained inactivated strains of S. aureus TC5, S. aureus TC8, E. coli, Str. agalactiae, Str. uberis, S. pyogenes, P. aeruginosa and A. pyogenes. time used for the immunization of a herd in Germany (Hoedemaker, 1999) . One vaccine dose measured 3.8x10 8 
cfu/mL formalin inactivated S. aureus cells. No
was for the number of SCC in the milk samples. Extensive testing was conducted by Edinger (2000) who examined the vaccine prepared from two strains of S. aureus, previously inactivated with formalin. The vaccine measured a total bacterial cell count (TBC/mL) in a concentration of 1x10 11 and 8.8x10 10 of the other strain. The somatic cells count (SCC) in the milk was lower in the vaccinated preparation and application of vaccines was given by Carter (2003), the vaccine contained human cytomegalovirus on whose plasmid DNA out a direct expression of the vaccine on the increase of antibodies against S. aureus which consisted of a polysaccharide capsule type 5 (T5), 8 (T8) and 336 (T336), were described by Lee (2005) in his work. The experiment described by Abubakar (2006) indicates that the group of rats vaccinated and revaccinated with an inactivated vaccine against Str. agalactiae exhibited a higher antibody titer compared to the group which received a single vaccine dose. The vaccine was prepared with a formalin inactivated strain of Str. agalactiae (1x10 9 /mL) and applied to rats subcutaneously in a dose of 0.2 mL. In a study Vakanjac et al. (2008) described the preparation of a vaccine applied in a dose of 5mL (S. aureus JR 3 in a quantity of 1x10 10 cfu/mL, 5 mg SM capsule S. aureus 2286 strain). Cows were vaccinated two months and re-vaccinated one month before the expected partum. There was no statistical of the control and vaccinated groups. of the levels of antibodies in immunized cows (0.697 OD) compared to the control group (0.438 OD). Ahmar (2008) described the preparation of a bivalent vaccine against mastitis caused by S. aureus and Str. agalactiae 527 increased compared with the control group. The vaccine prepared by Leitner (2011) contained part of the membrane of the surface protein rTRAP (recombinant Target RNAIII Activating Protein) and it is an integral component of protein 167 AA, being a landmark of pathogenic staphylococcal strains. Antibody levels in the group of cows, as opposed to the number of SCC, which was higher in the control group. Chen (2012) prepared a staphylococcal enterotoxin A (rSEA) recombinant vaccine and used as a carrier polylastic-co-glycolic acid (PLGA) microparticles. Test results showed a strong humoral response to increasing concentrations of antibodies against rSEA and increased survival of mice infected with lethal doses of S. aureus.
MATERIAL AND METHODS
Vaccine preparation -The vaccine was prepared with two autochthonous strains which have displayed distinct biochemical features of S. aureus SAU 7 and Str. agalactiae SAG 3. Both these strains were seeded on Brain-Heart Infusion (Serva). The prepared 5 L Brain-Heart Infusion was seeded with the isolated S. aureus incubated for 24h. After inactivation of the microorganism with formalin the culture After centrifugation the supernatant was discarded and the sediment resuspended of the vaccine.
The same procedure was repeated with the Str. agalactiae SAG 3 strain, and the resuspended sediment was used as the second component of the vaccine. In
The dose of the vaccine was 5mL/cow, containing inactivated bacterial S.aureus SAU 7 in a quantity of 1x10 10 Str. agalactiae SAG 3 in a quantity of 4 x 10 9 cfu/ml (second constituent). By preparing the vaccine in the described manner 151 vaccine doses (5 mL each) were obtained.
Vaccine sterility and toxicity tests
To test for sterility the vaccine was seeded into 2 test tubes containing serum broth, 2 test tubes containing nutritious broth, Jansen's media with added starch and Jansen media with glucose added, nutritious oblique agar and blood agar. In none of the listed media aerobic or anaerobic bacterial growth was recorded. This proved that the vaccine was sterile. 
Citology
The number of somatic cells was estimated by light miceoscopy, previously described by Vakanjac et al. (2008) .
Immunology tests
Due to a lack of commercial ELISA tests special custom made tests for the antibodies in the milk samples.
Preparation of direct ELISA test plates
The preparation of the antigen for ELISA consisted of Staphylococcus aureus SAU 7, and Streptococcus agalactiae SAG 3 vaccine strains, inoculated into 10mL brain-heart broth (Oxoid, UK), and incubated at 37°C for 24 hours. After incubation, 2 mL broth culture was centrifuged at 6000 rpm for 10 min. The supernatant was discarded and the cell sediment resuspended in 2 mL phosphate buffered saline-PBS, pH 7.4 (Oxoid, UK). Thereon the suspensions were again centrifuged at 6000 rpm for 10 min and the supernatant discarded. The procedure was repeated twice. The obtained sediments were resuspended in TRIS (Merck, Germany) and 2 mM EDTA (Merck, Germany) added. The solutions were incubated at 56°C for 30 min. After incubation the solution was well mixed suspension was incubated at 4°C, for 24 hours. After incubation the suspension was heated in a thermoblock (Techne, Germany) at 100°C for 30 min. Thereon the suspension was centrifuged at 6000 rpm for 10 min and the supernatant was collected. The supernatant contained the antigens diluted 1:10 with the coating buffer (mM Na 2 CO 3 /NaHCO 3, pH 9,6, Sigma Aldrich, Germany). To each well was at 4°C for 24 hours. After incubation the plates were rinsed three times with the incubated at 4°C for 24 hours. After incubation the plates were rinsed three times with the rinsing solution (PBS, pH 7.4).
Experiment
Sixty pregnant dairy Holstein-Freesian cows of similar age (4-5 years) were included in the study. Experimental group 1 (E1) consisted of 20 cows, vaccinated two months prior to calving, and revaccinated a month before the expected term of delivery. Experimental group 2 (E 2) consisted of 20 cows vaccinated one month before and revaccinateed two months after calving. The remaining 20 cows, considered as the control group (C), was vaccinated with a placebo vaccine (5 mL sterile saline).
Milk samples were taken from all animals before vaccination (before the clinical and sub-clinical mastitis. The milk samples were tested cytologically and bacteriologically in order to disclose the presence of S. aureus and Str. agalactiae.
RESULTS
In this chapter the given results are from a farm with a high yearly incidence of sub-clinical and clinical mastitis where the cows were vaccinated and revaccinated with stable strains S. aureus SAU 7 and Str. agalactiae SAG 3.
Microbiological testing
The experiment lasted for 8 months, from the dry period, to the onset of clinical or subclinical mastitis caused by S. aureus and Str. agalactiae. Milk samples taken from the control group (C) and experimental group 2 (E2) at the start of the trial tested positive for S. aureus S. aureus was isolated
S. aureus. Subclinical mastitis

S. aureus mastitis emerged
groups were not diagnosed with clinical mastitis (Table 1) . Table 1 Occurrence of clinical and subclinical mastitis, caused by S. aureus at the beginning and end of the experiment. At the beginning of the experiment the milk samples from the control and (E1) and (E2), Str. agalactiae the end of the experiment Str. agalactiae in the control group, while in the treated groups this microorganism was not isolated. Subclinical mastitis caused by Str. agalactiae was diagnosed in only two cows in the control group, while the causal agent was not isolated from cows from the vaccinated group. On the other hand, clinical mastitis caused by this microorganism was not diagnosed in any of the cows in the experiment (Table 2 ).
Milk somatic cell count (SCC)
The number of somatic cells (SCC) in 1 mL of milk was determined by cell counting under a light microscope by previously described means. The average value of SCC in 1 mL of milk obtained from cows in the control group (C) was 405 215 ± 41 893, while the value for (E1) was 613 204 ± 38 123, and for (E2) during the entire period. In the control group of cows at the beginning of the dry period SCC was 972 409 ± 178 844 in 1 mL of milk, while (E1) and (E2) was 871 011 ± 122 639 and 946 320 ± 124 567, respectively. In the performed experiments, the average number of somatic cells in the milk samples in early lactation (colostrum) was for the control group 9450609 ± 170 027 in 1 mL of milk, in (E1) was 690 317 ± 1140126, and in (E2) SCC was 9390356 ± 114,175 in 1 mL of milk was higher in the control group than in the treated groups ( Figure  1) . From the second month onward, the average number of SCC in 1 mL of milk in (E1) was greater than in the control (C) and (E2). After seven months, the average number of SCC in 1 mL of milk was lower in the control group (401 351 ± 104 104), while in (E1 and E2) leveled at 623,507 ± 92,569 and 626,555 ± 113,386 in 1 mL of milk. Table 3 describes the percentages of clinical and subclinical S. aureus mastitis cases at the start and end of the experiment, as well as the anti staphylococcal antybodies titer in the milk samples of tested cows. The antistaphylococcal antibodies titer was lowest in the control group (0.65 ± 0.18 OD) and the incidence of cows affected with S. aureus was 0.78 ± 0.21, and the percentage of mastitis caused by S. aureus with reduced the clinical form caused by S. aureus was not diagnosed. The highest titers of staphylococcal antibodies was measured in the (E2) and amounted to 0.81 ± 0.21. The percentage of mastitis caused by S. aureus caused by this microorganism was not reported. Table 4 presents the percentages of subclinical and clinical mastitis caused by Str. agalactiae at the beginning and end of the experiment, and the antistreptococcal antibody titers in the milk samples. From the table we see that in the control group anti-streptococcal antibody titer was the lowest (0.57 ± 0.39 OD), and the percentage of mastitis caused by Str. agalactiae in the milk was reduced from mastitis cases were not diagnosed. In (E1) streptococcal antibody titer was (1.00 ± 0.58OD) and subclincal and clinical Str.agalactiae mastitis was not reported. The highest of streptococcal antibody titer was measured in (E2) and amounted to 1.11 ± 0.64 OD, and subclinical and clinical mastitis cases were not reported in this group of animals. The tests have shown that the number of somatic cells (SCC) in the milk samples at the beginning of the dry period was approximately within the published literature data. In the control group SCC was 972 409 ± 178 844 in 1 mL of milk, in (E1) SCC was about 871 011 ± 122 639, while for (E2) SCC was 946 319 ± 124 567 in 1 mL of milk. In the performed experiments the average number of somatic cells in early lactation was in the control group 945 609 ± 170 027, in (E1) was 690 316 ± 114 126, while for (E2) SCC was 936,356 ± 114,175 in 1 mL of milk. Vakanjac et al. (2008) described an average SCC in the control group of 551.223 ±248.429 cells/mL and for the treated group was 582.022±297.312 cells/ mL milk, this being very close to the values obtained in the here reported trial. The average value of SCC in 1 mL of milk in the control group was 405 215 ± 41 893, in experimental group 1 (E1) was 613 204 ± 38 123, while in experimental group 2 (E2) was 5270681 ± 42 617, indicating that between groups there was Nordhaug (1994) , Giraudoa (1997), Hoedmaker (1999), Edinger (2000), Keskin (2007) and Prenafeta (2010) , number of SCC between groups.
Antibody milk titers
During the entire experiment the values of the level of antibodies in experimental groups 1 and 2 were higher than for the control group. Mean value (E1) 0.78 ± 0.21 OD, while the value in the (E2) was 0.81 ± 0.21 OD. Values of experiment was 0.91 OD, but during the experiment the value decreased to 0.59 OD. Staphylococcal antibody titer was 1.01 OD at the beginning of the experiment in the (E1), and during testing antibody levels decreased to 0.66 OD in contrast to the level of antibodies in (E2), which at the beginning of the test was 0.99. The lowest reported value during the trial period amounted to 0.72 OD.
the control group throughout the experiment were reported by Nordhaug (1994) 
